This week on MedTech Global Insights, we dissect the wave of "Refuse to Accept" letters from the US FDA that are derailing market entry plans. As the agency fully enforces its new cybersecurity mandates, many MedTech companies are finding their submissions unexpectedly rejected, causing costly delays and forcing a rethink of their entire regulatory strategy.

We explore the critical gap between existing technical documentation and the FDA's stringent new requirements. This episode moves beyond the headlines to reveal the specific, on-the-ground mistakes companies are making, from incomplete software documentation to flawed post-market planning. We use the real-world example of a European AI device company that was blocked from the US market last week, not because of its technology, but because of a single overlooked detail in its cybersecurity file, a painful lesson in the new realities of global regulation.

Key Questions Answered:

- Why are even top-tier companies getting "Refuse-to-Accept" letters from the FDA?

- What is the single biggest mistake companies make in their cybersecurity documentation?

- How can you leverage your EU MDR technical file for an FDA submission, and where does it fall short?

- Is your Software Bill of Materials (SBOM) actually compliant with FDA expectations?

- What specific details does the FDA require in a post-market surveillance plan?

- How does threat modeling for the FDA differ from other regulatory bodies?

- What are the hidden costs of an RTA letter beyond the regulatory delay?

Contact us at [email protected] or visit https://pureglobal.com/. You can also visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.